AMEX · NNVC
Healthcare · Biotechnology
$1.37
Down-$0.03 (-1.82%)
Updated Aug 13, 2026, 6:33 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NNVC closed at $1.37 after 21 trading sessions, down 20.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.41 | $1.43 | $1.345 | $1.37 | 241.74K |
| Aug 11, 2026 | $1.39 | $1.415 | $1.34 | $1.36 | 249.61K |
| Aug 10, 2026 | $1.31 | $1.51 | $1.31 | $1.40 | 800.81K |
| Aug 7, 2026 | $1.42 | $1.45 | $1.385 | $1.42 | 126.87K |
| Aug 6, 2026 | $1.40 | $1.45 | $1.365 | $1.40 | 232.6K |
| Aug 5, 2026 | $1.51 | $1.525 | $1.43 | $1.43 | 246.02K |
| Aug 4, 2026 | $1.54 | $1.56 | $1.50 | $1.52 | 296.95K |
| Aug 3, 2026 | $1.64 | $1.67 | $1.51 | $1.55 | 510.86K |
| Jul 31, 2026 | $1.52 | $1.60 | $1.51 | $1.52 | 133.07K |
| Jul 30, 2026 | $1.53 | $1.59 | $1.53 | $1.55 | 173.04K |
| Jul 29, 2026 | $1.62 | $1.6242 | $1.52 | $1.54 | 169.92K |
| Jul 28, 2026 | $1.45 | $1.65 | $1.45 | $1.61 | 625.34K |
| Jul 27, 2026 | $1.51 | $1.65 | $1.51 | $1.54 | 474.58K |
| Jul 24, 2026 | $1.50 | $1.58 | $1.47 | $1.48 | 314.43K |
| Jul 23, 2026 | $1.53 | $1.61 | $1.51 | $1.53 | 313.53K |
| Jul 22, 2026 | $1.54 | $1.60 | $1.48 | $1.52 | 595.34K |
| Jul 21, 2026 | $1.75 | $1.79 | $1.60 | $1.60 | 353.41K |
| Jul 20, 2026 | $1.79 | $1.84 | $1.70 | $1.75 | 432.09K |
| Jul 17, 2026 | $1.72 | $1.7914 | $1.6701 | $1.75 | 176.58K |
| Jul 16, 2026 | $1.72 | $1.85 | $1.6307 | $1.77 | 607.98K |
| Jul 15, 2026 | $1.77 | $1.7997 | $1.69 | $1.72 | 234.9K |
The latest Smart Investors Daily articles mentioning NNVC.
NNVC research
Company profile and research snapshot.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 6, 2026 | Noble Capital Markets | Outperform | — |
| May 7, 2024 | EF Hutton | Buy | — |
| Feb 16, 2024 | EF Hutton | Buy | — |
| Apr 18, 2023 | EF Hutton | Buy | — |
| Feb 28, 2023 | EF Hutton | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 28, 2026
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it is eagerly awaiting regulatory approval to begin a Phase II
Benzinga · Jul 22, 2026
NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned
Benzinga · Jul 13, 2026
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a Phase II
Benzinga · Jul 6, 2026
Noble Capital Markets analyst Robert LeBoyer initiates coverage on Nanoviricides (AMEX:NNVC) with a Outperform rating and announces Price Target of $6.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NNVC.
